SIOC English
有机化学
高级检索

有机化学 >

2019 , Vol. 39 >Issue 11: 3230 - 3236

DOI: https://doi.org/10.6023/cjoc201905013

研究论文

3-芳基-7-羟基喹啉类拓扑异构酶Ⅱα抑制剂的合成及抗肿瘤活性研究

  • 胡园 ,
  • 李震宇 ,
  • 丁艳娇 ,
  • 李志颖 ,
  • 刘志勇 ,
  • 沈月毛
展开
  • a山东大学药学院 天然产物化学教育部重点实验室 济南 250012
    b 山东大学附属省立医院药剂科 济南 250021

收稿日期: 2019-05-08

  网络出版日期: 2019-06-24

基金资助

国家重点基础研究发展计划(973计划);国家重点基础研究发展计划(2010CB833802);国家自然科学基金(81273384);国家自然科学基金(90913024);国家自然科学基金(91313303);国家杰出青年科学基金(30325044);长江学者与创新团队发展计划(IRT_17R68)

收起

Antitumor and Topoisomerase Ⅱα Inhibitory Activities of 3-Aryl-7-hydroxyquinolines

  • Yuan Hu ,
  • Zhenyu Li ,
  • Yanjiao Ding ,
  • Zhiying Li ,
  • Zhiyong Liu ,
  • Yuemao Shen
Expand
  • a Key Laboratory of Chemical Biology(Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012
    b Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021

Received date: 2019-05-08

  Online published: 2019-06-24

Supported by

the National Basic Research Program of China(973计划);the National Basic Research Program of China(2010CB833802);the National Natural Science Foundation of China(81273384);the National Natural Science Foundation of China(90913024);the National Natural Science Foundation of China(91313303);the National Science Foundation for Distinguished Young Scholars of China(30325044);the Program for Changjiang Scholars and Innovative Research Team in University(IRT_17R68)

Fold

摘要

人脱氧核糖核酸（DNA）拓扑异构酶Ⅱα（topoisomerase Ⅱα，Topo Ⅱα）是重要的抗肿瘤药物靶标之一.为发现高效、低毒的Topo Ⅱα抑制剂，通过对先导化合物6-（3，4-二羟基苯基）萘酚（CS1）进行骨架跃迁，设计合成了21个3-芳基-7-羟基喹啉衍生物.采用DNA松弛实验评价体外Topo Ⅱα抑制活性，结果显示大部分化合物对Topo Ⅱα活性有抑制作用；采用人三阴乳腺癌MDA-MB-231细胞和人宫颈癌HeLa细胞生长抑制实验体外评价抗肿瘤活性，结果表明3-（2，4-二甲氧基苯基）-7-羟基喹啉（4j）对HeLa细胞有明显毒性（IC50=0.8 μmol·L-1），3-（4-羟基苯基）-7-羟基喹啉（4e）对MDA-MB-231（IC50=1.1 μmol·L-1）和HeLa（IC50=4.2 μmol·L-1）细胞均有明显毒性，阳性对照CS1对MDA-MB-231和HeLa细胞的IC50值分别为3.8和2.5 μmol·L-1.研究结果为设计合成新的喹啉类高效拓扑异构酶Ⅱα抑制剂提供了新思路.

关键词： 拓扑异构酶Ⅱα; 设计合成; 结构优化; 抗肿瘤活性

本文引用格式

胡园 , 李震宇 , 丁艳娇 , 李志颖 , 刘志勇 , 沈月毛 . 3-芳基-7-羟基喹啉类拓扑异构酶Ⅱα抑制剂的合成及抗肿瘤活性研究[J]. 有机化学, 2019 , 39(11) : 3230 -3236 . DOI: 10.6023/cjoc201905013

Abstract

Human deoxyribonucleic acid (DNA) topoisomerase Ⅱα (Topo Ⅱα) is one of the important therapeutic targets for the treatment of cancers. To further discover Topo Ⅱα inhibitors with high efficiency and low toxicity, twenty-one 3-aryl-7-hydroxyquinolines were designed and synthesized by scaffold hopping of the lead compound 4-(6-hydroxynaph-thalen-2-yl)benzene-1, 2-diol (CS1). These compounds were evaluated for their inhibitory activity against Topo Ⅱα activity in DNA relaxation assays, and evaluated for the antitumor activity in in vitro growth inhibition assays against human triple negative breast cancer MDA-MB-231 cells and human cervical cancer HeLa cells. DNA relaxation assays showed that most compounds have inhibitory activity against Topo Ⅱα. In vitro growth inhibition assays showed that 3-(2, 4-dimethoxyphenyl)-7-hydroxyquinoline (4j) has obvious cytotoxicity against HeLa cells (IC50=0.8 μmol·L-1), and 3-(4-hydroxyphenyl)-7-hydroxyquinoline (4e) has evident cytotoxicity against both MDA-MB-231 (IC50=1.1 μmol·L-1) and HeLa cell lines (IC50=4.2 μmol·L-1). These results provide insight into the development of novel quinoline topoisomerase Ⅱα inhibitors.

Key words： topoisomerase Ⅱα; design and synthesis; structure optimization; antitumor activity

参考文献

[1] World Health Organization (WHO), WHO cancer 2018, Available from: , 2018.
[2] Costa R. Shah A. N. Santa-Maria C. A. Cruz M. R. Mahalingam D. Carneiro B. A. Chae Y. K. Cristofanilli M. Gradishar W. J. Giles F. J. Cancer Treat Rev. 2017 53 111.
[3] Wang Y. Sun H. Xiao Z. Zhang G. Zhang D. Bao X. Li F. Wu S. Gao Y. Wei N. Cell Commun. Signal 2018 16 52.
[4] Infante Lara L. Sledge A. Laradji A. Okoro C. O. Osheroff N. Bioorg. Med. Chem. Lett. 2017 27 586.
[5] Ortega J. A. Riccardi L. Minniti E. Borgogno M. Arencibia J. M. Greco M. L. Minarini A. Sissi C. De Vivo M. J. Med. Chem. 2018 61 1375.
[6] Shapiro A. B. Austin C. A. Anal. Biochem. 2014 448 23.
[7] Guan M. Qiu J. Lu C. Zhao B. Shen Y. Chin. J. Org. Chem. 2018 38 3039.
[7] 关 梦佳 邱 进 鲁 春华 赵 保兵 沈 月毛 有机化学 2018 38 3039.
[8] Park S. Hong E. Kwak S. Y. Jun K. Y. Lee E. S. Kwon Y. Na Y. Eur. J. Med. Chem. 2016 123 211.
[9] Wu X. Yalowich J. C. Hasinoff B. B. J. Inorg. Biochem. 2011 105 833.
[10] Coustry F. Maity S. N. de Crombrugghe B. J. Biol. Chem. 1995 270 468.
[11] McClendon A. K. Osheroff N. Mutat. Res. 2007 623 83.
[12] Chen W. Shen Y. Li Z. Zhang M. Lu C. Shen Y. Eur. J. Med. Chem. 2014 86 782.
[13] Hao H. Chen W. Zhu J. Lu C. Shen Y. Eur. J. Med. Chem. 2015 102 277.
[14] Tseng C. H. Chen Y. R. Tzeng C. C. Liu W. Chou C. K. Chiu C. C. Chen Y. L. Eur. J. Med. Chem. 2016 108 258.
[15] Khadka D. B. Woo H. Yang S. H. Zhao C. Jin Y. Le T. N. Kwon Y. Cho W.-J. Eur. J. Med. Chem. 2015 92 583.
[16] Zhao H. Drug Discovery Today 2007 12 149.
[17] Shen Y. Chen W. Zhao B. Hao H. Li Z. Lu C. Shen Y. Biochem. Biophys. Res. Commun. 2014 453 302.
[18] Li Z. Ding Y. Bu H. Shen Y. Chin. J. Org. Chem. 2018 38 3204.
[18] 李 志颖 丁 艳娇 卜 华港 沈 月毛 有机化学 2018 38 3204.
[19] Frotscher M. Ziegler E. Marchais-Oberwinkler S. Kruchten P. Neugebauer A. Fetzer L. Scherer C. Mueller-Vieira U. Messinger J. Thole H. Hartmann R. W. J. Med. Chem. 2008 51 2158.
[20] Krishnan R. Seshadri S. Dyes Pigm. 1986 7 69.
[21] Xiao X. Cushman M. J. Am. Chem. Soc. 2005 127 9960.
[22] Huang Y. Wang J. Li G. Zheng Z. Su W. FEMS Immunol. Med. Microbiol. 2001 31 163.
[23] Carmichael J. DeGraff W. G. Gazdar A. F. Minna J. D. Mitchell J. B. Cancer Res. 1987 47 943.
Options
文章导航

/

〈 〉